Toll-like receptors 7, 8, and 9 expression and function in primary human cervical cancer Langerhans cells : Evidence of anergy

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 184-192

  Kumar, Mahesh M ^a   Adurthi, Sreenivas ^a   Ramachandran, Surya ^b   Mukherjee, Geetashree ^a   Joy, Omana ^c   Krishnamurthy, H ^d   Krishna, Sudhir ^d   Bafna, U D ^a   Uma, Devi K ^a   Jayshree, R S ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^b RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^c INDIAN INSTITUTE OF SCIENCE   (India)

^d TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

Cervical cancer; CpG ODN; Human papillomavirus type 16; Immune tolerance; Langerhans cells; TLR7; TLR8; TLR9; Toll like receptor

Indexed keywords

ALPHA INTERFERON; CD1C ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; LANGERIN; MESSENGER RNA; T6 ANTIGEN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ACUTE MONOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IN VITRO STUDY; LANGERHANS CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UTERINE CERVIX CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CLONAL ANERGY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LANGERHANS CELLS; LIGANDS; MIDDLE AGED; PRIMARY CELL CULTURE; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 84872318235     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31827a2003     Document Type: Article

References (25)

1. Connor JP, Ferrier K, Kane JP, et al. Evaluation of Langerhans cells in the cervical epithelium of women with cervical intraepithelial neoplasia. GynecolOncol. 1999;75:130-135.
2. Zhao X, Deak E, Soderberg K, et al. Vaginal sub mucosal dendritic cells, but not Langerhans cells, induce protective TH1 responses to herpes simplex virus-2. J Exp Med. 2003;197:153-162.
3. Kawai T, Akira S. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol. 2009;21:317-337.
4. Peiser M, Koeck J, Kirschning CJ, et al. Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4+ T cell stimulatory capacity. J Leukoc Biol. 2008;5:1118-1127.
5. Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178:3186-3197.
6. Rozis G, Benlahrech A, Duraisingham S, et al. Human Langerhans cells and dermal-type dendritic cells generated from CD34 stem cells express different Toll-like receptors and secrete different cytokines in response to Toll-like receptor ligands. Immunology. 2008;124:329-338.
7. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
8. Corbett NP, Blimkie D, Ho KC, et al. Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One. 2010;5:1-12.
9. Shi SR, Datar R, Liu C, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution. Histochem Cell Biol. 2004;94:211-218.
10. Kobayashi A, Weinberg V, Darragh T, et al. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 2008;1:412-420.
11. zur Hausen H. Viruses in human cancers. Science. 1991;254:1167-1173.
12. de Jong MA, de Witte L, Taylor ME, et al. Herpes simplex virus type 2 enhances HIV-1 susceptibility by affecting Langerhans cell function. J Immunol. 2010;185:1633-1641.
13. Yang K, Puel A, Zhang S, et al. Human TLR-7, -8, and -9 mediated induction of IFN-alpha/beta and -l is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity. 2005;23:465-478.
14. Isogawa M, Robek MD, Furuichi Y, et al. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79:7269-7272.
15. Martin HJ, Lee JM,Walls D, et al. Manipulation of the Toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol. 2007;81:9748-9758.
16. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;21:637-650.
17. Mizumoto N, Takashima A. CD1a and langerin: acting as more than Langerhans cell markers. J Clin Invest. 2004; 113:658-660.
18. Romani N, Clausen BE, Stoitzner P. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev. 2010;234:120-141.
19. Fahey LM, Raff AB, Da Silva DM, et al. Reversal of human Papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol. 2009;182:2919-2928.
20. Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity. 2008;29:637-649.
21. Adurthi S, Mukherjee G, Krishnamurthy H, et al. Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells. Int J Gynecol Cancer. 2012;22:1130-1137.
22. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543-547
23. Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. Expert Opin Ther Targets. 2010;14:787-796.
24. Ortiz-Sánchez E, Chávez-Olmos P, Pina-Sánchezy P, et al. Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions. Int J Gynecol Cancer. 2007;17:571-580.
25. Moore RA, Edwards JE, Hopwood J, et al. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:1-9.